Remedium Bio raised an initial $10 million Series A financing to push its durable protein therapeutics platform toward first-in-human development. The company is framing the round as early runway expansion to translate platform biology into clinical candidates. The investment supports ongoing platform optimization and preparation for the first human studies, where durability and exposure/target engagement typically become decisive. For biotech investors, the deal adds to the set of platform-first companies building protein modalities aimed at improved residence time and practical dosing regimens.